Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: jad who wrote (1195)	10/22/1997 11:19:00 AM
From: David B.	Read Replies (1) \| Respond to of 1693

No mention by Quidel of the P&G comarketing effort. Here is a blurb on a small test kit company that anticipates fast growth: FOCUS recommends drug-test kit company as investment FOCUS Capital Management Inc., a small money-management firm in New York City, has recommended American Bio Medica Corp. (OTC BB: ABMC) of Ancramdale, Columbia County, as a buy for "the speculative portion of our clients' portfolios." Patrick Sabatino, an investment analyst at FOCUS Capital, predicted that American Bio Medica would achieve earnings per share of 5 cents with revenue of $4.5 million in the current fiscal year, and earnings per share of 14 cents with revenue of $11 million next year. American Bio Medica manufactures drug-testing kits. FOCUS Capital referred to the company's Rapid Drug Screen as "superior to present competitive products."